-

03:37:54 PM

NBIX Stock News

NBIX - Neurocrine Biosciences, Inc.

09/21/23 9:15 AM

Nasdaq : NBIX

Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

Neurocrine Biosciences, Inc., today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug crinecerfont in adolescent patients with classic congenital adrenal hyperplasia due to 21- hydroxylase deficiency. The analysis suggests that adolescents with classic CAH who have more...

RHEA-AI

neutral

09/14/23 8:30 AM

Nasdaq : NBIX

clinical trial

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation

Neurocrine Biosciences, Inc. today announced the U.S. Food and Drug Administration has accepted its New Drug Application for INGREZZA ® oral granules, a new sprinkle formulation of INGREZZA ® capsules for oral administration. The agency set a...

RHEA-AI

negative

09/12/23 7:30 AM

Nasdaq : NBIX

clinical trial

Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

Neurocrine Biosciences, Inc. today announced positive...

RHEA-AI

neutral

09/11/23 8:30 AM

Nasdaq : NBIX

clinical trial

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

Neurocrine Biosciences, Inc., today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117570 in healthy adult participants. NBI-1117570 is an investigational, oral, muscarinic M1/M4...

RHEA-AI

neutral

08/31/23 4:01 PM

Nasdaq : NBIX

conferences

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

2023 Wells Fargo Healthcare Conference on September 7 in Boston. Morgan Stanley 21 st Annual Global Healthcare Conference on September 12 in New York. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the Morgan Stanley 21 st Annual Global Healthcare Conference at 10:50 a.m. Eastern Time on Tuesday, September...

RHEA-AI

neutral

08/28/23 8:30 AM

Nasdaq : NBIX

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

Neurocrine Biosciences, Inc. today announced new data on now FDA-approved INGREZZA ® capsules for the treatment of adults with chorea associated with Huntington's disease, including exploratory results from the...

RHEA-AI

neutral

08/18/23 4:34 PM

Nasdaq : NBIX

fda approval

Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease

Neurocrine Biosciences, Inc. today announced the U.S. Food and Drug Administration has approved INGREZZA ® capsules for the treatment of adults with chorea associated with Huntington's disease. 1 INGREZZA is the only selective vesicular monoamine transporter 2 inhibitor that offers an effective starting dosage that can...

RHEA-AI

neutral

08/01/23 7:00 AM

Nasdaq : NBIX

earnings

Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance

Neurocrine Biosciences, Inc. today announced its financial results for the second quarter ended June 30, 2023 and raised net sales guidance for INGREZZA in 2023.. Second quarter 2023 GAAP net income and earnings per share of $96 million and $0.95,...

RHEA-AI

neutral

07/11/23 4:05 PM

Nasdaq : NBIX

management

Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors

Neurocrine Biosciences, Inc. today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors. "Christine Poon brings a wealth of industry experience to Neurocrine's Board of Directors," said William H. Rastetter, Chairman of the Board of...

RHEA-AI

neutral

07/11/23 4:01 PM

Nasdaq : NBIX

earnings

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results

Neurocrine Biosciences, Inc. announced today that it has scheduled its second quarter 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time on August 1, 2023.. The schedule for the press release and conference call/ webcast is as follows:.

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

NBIX Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitehttp://www.neurocrine.com/
Security nameNeurocrine Biosciences, Inc.
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
CountryUS

About Neurocrine Biosciences, Inc.

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders